Fig. 6

Proscillaridin A Targets Leukemic Stem Cells (LSCs). a Cell viability assay of T-ALL pre-LSC co-cultured with MS5-DL4 cells. Proscillaridin A (3 nM or 10 nM) was added 24 h after co-culture, and cells were sorted for pre-LSC viability 4-days post treatment (*indicates P < 0.05; One-way ANOVA; n ≤ 3). b Cell viability assay of AML 8227 population composed of LSCs (CD34⁺) and non-LSCs (CD34⁻/CD15^+/−). AML 8227 were treated with proscillaridin A (10 nM to 100 nM) for 6 days and cell viability was measured for each cell subgroup by flow cytometry. c Gene set enrichment analysis of MYC pathway between two AML 8227 subgroups: LSC-enriched population CD34⁺/CD38⁻ compared to non-LSC population CD34⁻. Enrichment score (ES) and false discovery rate (FDR) rates are shown on the graph. d Dose response curves and IC₅₀ values after a 6-day proscillaridin A treatment (ranging from 10 nM to 100 nM) in each AML 8227 subgroup (n = 3)